122 related articles for article (PubMed ID: 35777022)
1. The evaluation of urinary calprotectin levels for prediction of acute cisplatin-induced nephrotoxicity.
Koçak G; Bilik G; Yeşilova A; Oyman F; Can M; Cihan Ş
Medicine (Baltimore); 2022 Jul; 101(26):e29814. PubMed ID: 35777022
[TBL] [Abstract][Full Text] [Related]
2. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL).
Niggebrugge-Mentink KL; Beex-Oosterhuis MM; Ter Horst PGJ; van de Poll MEC; Dieleman HG; van Kesteren C
J Clin Pharm Ther; 2020 Oct; 45(5):1153-1158. PubMed ID: 32533904
[TBL] [Abstract][Full Text] [Related]
3. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.
Mense ES; Smit AAJ; Crul M; Franssen EJF
J Clin Pharm Ther; 2019 Apr; 44(2):249-257. PubMed ID: 30578577
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients.
Toprak Z; Cebeci E; Helvaci SA; Toprak ID; Kutlu Y; Sakin A; Tukek T
Int Urol Nephrol; 2017 Jun; 49(6):1041-1047. PubMed ID: 28255639
[TBL] [Abstract][Full Text] [Related]
5. Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study.
Shoji S; Hosojima M; Kabasawa H; Kondo R; Miura S; Watanabe S; Aoki N; Kaseda R; Kuwahara S; Tanabe N; Hirayama Y; Narita I; Kikuchi T; Kagamu H; Saito A
BMC Cancer; 2019 Dec; 19(1):1170. PubMed ID: 31791266
[TBL] [Abstract][Full Text] [Related]
6. Urinary Calprotectin Differentiates Between Prerenal and Intrinsic Acute Renal Allograft Failure.
Seibert FS; Rosenberger C; Mathia S; Arndt R; Arns W; Andrea H; Pagonas N; Bauer F; Zidek W; Westhoff TH
Transplantation; 2017 Feb; 101(2):387-394. PubMed ID: 26901081
[TBL] [Abstract][Full Text] [Related]
7. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury.
Heller F; Frischmann S; Grünbaum M; Zidek W; Westhoff TH
Clin J Am Soc Nephrol; 2011 Oct; 6(10):2347-55. PubMed ID: 21885792
[TBL] [Abstract][Full Text] [Related]
8. Urinary calprotectin, NGAL, and KIM-1 in the differentiation of primarily inflammatory vs. non-inflammatory stable chronic kidney diseases.
Seibert FS; Sitz M; Passfall J; Haesner M; Laschinski P; Buhl M; Bauer F; Rohn B; Babel N; Westhoff TH
Ren Fail; 2021 Dec; 43(1):417-424. PubMed ID: 33663323
[TBL] [Abstract][Full Text] [Related]
9. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
10. A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study.
Inoue T; Miyazaki J; Ichioka D; Narita S; Kageyama S; Sugimoto M; Mitsuzuka K; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Matsui Y; Fujie K; Habuchi T; Nishiyama H
BMC Cancer; 2018 Mar; 18(1):290. PubMed ID: 29540229
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin nephrotoxicity in a patient with a single kidney.
Udeani GO; Singh K; Mullane MR; Lad TE
Ann Pharmacother; 1996; 30(7-8):782-6. PubMed ID: 8826561
[TBL] [Abstract][Full Text] [Related]
12. Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.
Ogawa T; Niho S; Nagai S; Kojima T; Nishimura Y; Ohe Y; Kondo N; Yamaguchi T; Endo K; Izumi K; Minami H
Int J Clin Oncol; 2013 Dec; 18(6):977-82. PubMed ID: 23053402
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Phase 2 Study of 5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate for the Prevention of Nephrotoxicity Induced by Cisplatin-Based Chemotherapy of Lung Cancer.
Kawamura K; Matsushima H; Sakai H; Iwashima A; Nakamura S; Kojima T; Sasaki S; Shigenaga T; Natsume I; Sasaki T; Ohsaki Y; Iwanaga K; Nishi K; Mitsuishi Y; Taniguchi H; Sato K; Yamauchi M; Nakajima M; Takahashi K
Oncology; 2022; 100(11):620-632. PubMed ID: 36099876
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of fosfomycin on cisplatin-induced nephrotoxicity in patients with lung cancer.
Rojanasthien N; Kumsorn B; Atikachai B; Leotrakul S; Thongprasert S
Int J Clin Pharmacol Ther; 2001 Mar; 39(3):121-5. PubMed ID: 11396752
[TBL] [Abstract][Full Text] [Related]
15. Urinary calprotectin and posttransplant renal allograft injury.
Tepel M; Borst C; Bistrup C; Marcussen N; Pagonas N; Seibert FS; Arndt R; Zidek W; Westhoff TH
PLoS One; 2014; 9(11):e113006. PubMed ID: 25402277
[TBL] [Abstract][Full Text] [Related]
16. Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury.
Westhoff JH; Seibert FS; Waldherr S; Bauer F; Tönshoff B; Fichtner A; Westhoff TH
Eur J Pediatr; 2017 Jun; 176(6):745-755. PubMed ID: 28409285
[TBL] [Abstract][Full Text] [Related]
17. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients.
Moon HH; Seo KW; Yoon KY; Shin YM; Choi KH; Lee SH
World J Gastroenterol; 2011 Aug; 17(30):3510-7. PubMed ID: 21941418
[TBL] [Abstract][Full Text] [Related]
18. Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury.
Yanishi M; Kinoshita H
BMC Nephrol; 2022 Mar; 23(1):125. PubMed ID: 35361160
[TBL] [Abstract][Full Text] [Related]
19. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
Shinke H; Masuda S; Togashi Y; Ikemi Y; Ozawa A; Sato T; Kim YH; Mishima M; Ichimura T; Bonventre JV; Matsubara K
Cancer Chemother Pharmacol; 2015 Nov; 76(5):989-96. PubMed ID: 26407820
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of Urinary Calprotectin after Renal Ischaemia.
Ebbing J; Seibert FS; Pagonas N; Bauer F; Miller K; Kempkensteffen C; Günzel K; Bachmann A; Seifert HH; Rentsch CA; Ardelt P; Wetterauer C; Amico P; Babel N; Westhoff TH
PLoS One; 2016; 11(1):e0146395. PubMed ID: 26745147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
